Peptron Inc Total Liabilities
Peptron Inc total liabilities. Based on the latest financial reports, Peptron Inc (087010) has total liabilities worth ₩38.50 Billion KRW (≈ $26.09 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Peptron Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Peptron Inc (2014–2025)
Total liabilities of Peptron Inc from 2014 to 2025. This chart illustrates how Peptron Inc's total liabilities have evolved over time, based on quarterly financial data. Explore investment intensity of Peptron Inc to see how much of total assets are deployed in long-term investments.
Peptron Inc Competitors by Total Liabilities
The table below lists competitors of Peptron Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MAP Aktif Adiperkasa Tbk PT
JK:MAPA
|
Indonesia | Rp4.94 Trillion |
|
KPC Pharmaceuticals Inc
SHG:600422
|
China | CN¥4.54 Billion |
|
PNC Process Systems Co Ltd
SHG:603690
|
China | CN¥9.60 Billion |
|
Econergy Renewable Energy Ltd
TA:ECNR
|
Israel | ILA666.39 Million |
|
Jiangsu Bojun Industrial Technology Co. Ltd
SHE:300926
|
China | CN¥6.70 Billion |
|
Oric Pharmaceuticals Inc
NASDAQ:ORIC
|
USA | $23.43 Million |
|
Life Healthcare
JSE:LHC
|
South Africa | ZAC11.49 Billion |
|
INVENTIVA ADS/1 O.N.
F:6IVA
|
Germany | €278.03 Million |
Liability Composition Analysis (2014–2025)
This chart breaks down Peptron Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 087010 current and non-current assets.
Liquidity & Leverage Metrics
Peptron Inc Total Liabilities Ratios Explained
Peptron Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.30 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Peptron Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Peptron Inc (2014–2025)
The table below shows the annual total liabilities of Peptron Inc from 2014 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩36.97 Billion ≈ $25.05 Million |
+115.15% |
| 2024-12-31 | ₩17.18 Billion ≈ $11.65 Million |
+4.98% |
| 2023-12-31 | ₩16.37 Billion ≈ $11.09 Million |
+7.94% |
| 2022-12-31 | ₩15.17 Billion ≈ $10.28 Million |
-2.70% |
| 2021-12-31 | ₩15.59 Billion ≈ $10.56 Million |
-61.58% |
| 2020-12-31 | ₩40.57 Billion ≈ $27.49 Million |
+23.31% |
| 2019-12-31 | ₩32.90 Billion ≈ $22.30 Million |
+23.40% |
| 2018-12-31 | ₩26.66 Billion ≈ $18.07 Million |
+549.70% |
| 2017-12-31 | ₩4.10 Billion ≈ $2.78 Million |
-12.56% |
| 2016-12-31 | ₩4.69 Billion ≈ $3.18 Million |
+5.96% |
| 2015-12-31 | ₩4.43 Billion ≈ $3.00 Million |
+0.77% |
| 2014-12-31 | ₩4.39 Billion ≈ $2.98 Million |
-- |
About Peptron Inc
Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, … Read more